October 18, 2017 4:26 AM ET


Company Overview of Impel Neuropharma Inc.

Company Overview

Impel Neuropharma Inc. develops a nasal delivery device for the delivery of pharmaceuticals to the brain. The company has a strategic alliance with 3M Drug Delivery Systems. Impel Neuropharma Inc. was incorporated in 2008 and is based in Normandy Park, Washington.

867 Shoremont Avenue

Normandy Park, WA 98166

United States

Founded in 2008



Key Executives for Impel Neuropharma Inc.

President & CEO
Age: 54
Executive Chairman
Age: 61
Co-Founder, Executive VP & Chief Scientific Officer
Co-Founder and Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2017.

Impel Neuropharma Inc. Key Developments

Impel NeuroPharma, Inc. Appoints Jon Congleton as President and Chief Executive Officer

Impel NeuroPharma Inc. announced the appointment of Jon Congleton as the company’s new President and Chief Executive Officer (CEO). Congleton has over 30 years’ experience in biopharmaceutical company leadership including pipeline development, commercial strategy and general management. Most recently he was President and CEO of Nivalis Therapeutics where he successfully executed the company’s IPO and clinical programs.

Impel Neuropharma Inc. Presents at 12th Annual Neurotech Investing and Partnering Conference, Jun-01-2017 09:30 AM

Impel Neuropharma Inc. Presents at 12th Annual Neurotech Investing and Partnering Conference, Jun-01-2017 09:30 AM. Venue: Park Central Hotel, San Francisco, California, United States. Speakers: John D. Hoekman, Co-Founder and Chief Scientific Officer.

Impel NeuroPharma Appoints Timothy S. Nelson to its Board of Directors

Impel NeuroPharma announced the appointment of Timothy S. Nelson as Independent Director of the Board of Directors. Mr. Nelson has over 20 years of experience with drug delivery, medical devices and drug device combinations. Most recently, Mr. Nelson served as MAP Pharmaceuticals’ President and CEO and as a member of its Board of Directors from April 2005 until March 2013. Prior to MAP, he served as Senior Vice President of Commercial and Business Development at DURECT Corporation and has held various senior management positions with Medtronic, including Business Director of the Neurological Division for Europe, the Middle East and Africa, and as Manager of Drug Delivery Ventures. Mr. Nelson has served on several boards, including Chairman of the Board of Civitas, a private biopharmaceutical company focused on treating undermet medical needs in neurological indications from December 2013 to October 2014.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
November 16, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Impel Neuropharma Inc., please visit www.impelneuropharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.